included. This drug can block the blood vessel supply and eventually starve the tumor in the body. Dayoutong can be combined with platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer, and can also be combined with fluoropyrimidine-based chemotherapy for the treatment of patients with metastatic colorectal cancer.

Dayoutong is a biological analogue of bevacizumab injection, also known as recombinant humanized monoclonal antibody injection against VEGF. VEGF is an important factor in angiogenesis, which is over-expressed in most human tumor endothelial cells.

anti-VEGF antibody can selectively bind VEGF with high affinity, and block the signal pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK by blocking the binding of VEGF to its receptors on the surface of vascular endothelial cells, thus inhibiting the growth, proliferation, migration and angiogenesis of vascular endothelial cells, reducing vascular permeability, blocking the blood supply of tumor tissues, inhibiting the proliferation and metastasis of tumor cells and inducing tumor cell apoptosis.

Bevacizumab injection, the original research drug, has been approved for the treatment of many solid tumors including non-small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell cancer, cervical cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer and so on, and its remarkable efficacy and good safety have been generally recognized. However, the cost of bevacizumab injection is still beyond the affordability of many ordinary patients, and there is a huge unmet clinical demand in China. Dayoutong _ is a humanized monoclonal antibody injection of recombinant anti-vascular endothelial growth factor (VEGF) independently developed by Cinda Bio-Pharmaceutical Co., Ltd., and it is a biological analogue of bevacizumab.

The marketing of Dayoutong _ provides high-quality and affordable bevacizumab injection for more patients in China. It is worth mentioning that Cinda's recombinant human anti-tumor necrosis factor-α (TNF-α) monoclonal antibody drug Sulixin _ (adalimumab injection, English trademark: SULINNO_) has also been officially approved by the National Medical Products Administration (NMPA) for the treatment of children's plaque psoriasis and adults who are not fully responsive to glucocorticoid, need to control the use of glucocorticoid, or are not suitable for glucocorticoid treatment.